Use of Albumin in Patients with Ascites

Indications for Albumin Therapy

• The American Association for the Study of Liver Diseases recommends administering 6-8 g of albumin per liter of ascites drained after completing a large-volume paracentesis (>5 liters) to prevent circulatory dysfunction, which can lead to renal failure, hepatorenal syndrome, dilutional hyponatremia, and hepatic encephalopathy 1, 2
• The European Association for the Study of the Liver suggests using a 20% or 25% albumin solution for paracentesis 2
• High-quality evidence supports the use of albumin in large-volume paracentesis, with a significant reduction in adverse effects and mortality 1, 2
• The International Club of Ascites recommends considering albumin (8 g/L) in high-risk patients, even with <5 liters of ascites, such as those with acute-on-chronic liver failure or high risk of acute kidney injury post-paracentesis 2

Peritonitis and Infections

• The American Association for the Study of Liver Diseases recommends a specific protocol for spontaneous bacterial peritonitis (SBP): 1.5 g/kg of albumin within the first 6 hours of diagnosis, followed by 1 g/kg on day 3, which reduces the incidence of hepatorenal syndrome and mortality 2, 3
• Patients with higher bilirubin levels (>4 mg/dL) and/or creatinine (>1.0 mg/dL) may benefit more from albumin therapy in SBP 3
• Albumin should not be used in other infections (non-SBP) in cirrhotic patients, as it does not reduce acute kidney injury or mortality and is associated with more pulmonary edema 3

Ascites Management

• The European Association for the Study of the Liver recommends standard treatment for uncomplicated ascites with sodium restriction (≤5 g/day or ≤2 g sodium/day) and diuretics (spironolactone 50-400 mg/day ± furosemide 20-160 mg/day) 1
• Albumin should not be used routinely in patients with uncomplicated ascites treated with diuréticos, as studies have not shown consistent benefits in survival or cost-effectiveness 3

Alternative Therapies

• Artificial plasma expanders are inferior to albumin, with higher activation of the renin-angiotensin-aldosterone system and higher incidence of post-paracentesis syndrome 4
• Hydroxyethyl starch has been shown to be inferior to albumin in improving systemic circulatory hemodynamics 3

IV Fluid Selection in Patients with Ascites

Primary Recommendation: Albumin Over Crystalloids

• The British Society of Gastroenterology recommends using albumin (20% or 25% solution) as the preferred colloid for volume expansion in cirrhotic patients with ascites, particularly after large-volume paracentesis (>5 liters) at 8 g per liter removed 5
• The British Society of Gastroenterology explicitly recommends against normal saline in ascites management, as it worsens salt retention and can exacerbate ascites 5

When Albumin is Mandatory

• In cases of spontaneous bacterial peritonitis (SBP), the administration of 1.5 g/kg albumin within 6 hours of diagnosis, followed by 1 g/kg on day 3, reduces hepatorenal syndrome and mortality 5
• In patients with severe hyponatremia with renal dysfunction (Na <125 mmol/L with creatinine >150 μmol/L or rising), volume expansion with albumin or colloids is preferred over crystalloids 6

Limited Role for Crystalloid Solutions

• If crystalloids must be used for volume expansion in hyponatremia with renal impairment, normal saline (154 mmol/L sodium) or colloids containing equivalent sodium are acceptable despite worsening salt retention—the priority is preventing irreversible renal failure over managing ascites 6

Hyponatremia Management Algorithm

• For serum sodium 126-135 mmol/L, continue diuretics, no water restriction, no IV fluids needed 6
• For serum sodium 121-125 mmol/L with elevated creatinine (>150 μmol/L or rising), stop diuretics immediately and give volume expansion with albumin or colloid 6
• For serum sodium <120 mmol/L, stop diuretics and provide volume expansion with albumin/colloid, but avoid increasing sodium by >12 mmol/L per 24 hours to prevent central pontine myelinolysis 6
• In cases of severe symptomatic acute hyponatremia, hypertonic saline (3%) may be used, but only for acute symptomatic cases with slow correction 5

Critical Pitfalls to Avoid

• Do not routinely restrict fluids unless severe hyponatremia (<125 mmol/L) with clinical hypervolemia exists—fluid restriction can worsen effective hypovolemia and increase ADH secretion 5, 6
• Do not use normal saline for routine volume expansion in cirrhotic ascites—it contains 154 mmol/L sodium and will worsen fluid overload 5

Albumin Use in Cirrhosis with Ascites: Indications, Dosing, and Monitoring

Indications and Evidence Strength

• Albumin (8 g per litre of ascites removed) is indicated after large‑volume paracentesis > 5 L and markedly reduces post‑paracentesis circulatory dysfunction, renal failure, and mortality; evidence is high‑quality (strong recommendation)【7】.
• In spontaneous bacterial peritonitis, give 1.5 g/kg albumin within 6 h of diagnosis followed by 1.0 g/kg on day 3; this regimen lowers the incidence of hepatorenal syndrome and mortality, supported by moderate‑quality evidence【7】.
• For paracentesis < 5 L, albumin should be considered only in patients at high risk for acute‑on‑chronic liver failure or acute kidney injury【7】.

Dosing Recommendations

• Large‑volume paracentesis: administer 8 g of albumin per litre of fluid removed, using a 20 %–25 % albumin solution【7】.
• Spontaneous bacterial peritonitis: 1.5 g/kg albumin within 6 h of diagnosis, then 1.0 g/kg on day 3【7】.
• Normal saline is contraindicated for routine volume expansion in cirrhotic ascites; albumin is the preferred colloid【7】.

Standard Ascites Management (Non‑Albumin)

• First‑line therapy is dietary sodium restriction (≤ 2 g/day) combined with diuretics【7】.
• Start spironolactone 100 mg daily and titrate up to 400 mg for uncomplicated ascites【7】.
• For recurrent severe ascites or hospitalized patients needing rapid diuresis, combine spironolactone (100–400 mg) with furosemide (40–160 mg)【7】.
• Approximately 45–50 % of patients on diuretics require dose adjustment or discontinuation because of adverse events【7】.

Monitoring and Safety

• Monitor all patients receiving diuretics for hypovolemic hyponatremia, renal impairment, and electrolyte disturbances【7】.
• In hypovolemic hyponatremia, discontinue diuretics and expand plasma volume with albumin【7】.
• Hypertonic saline (3 %) should be reserved for severely symptomatic acute hyponatremia and administered with careful, slow correction【7】.

Guideline Recommendations and Evidence Grading

• The 2021 British Society of Gastroenterology guidelines and the 2025‑2026 American Association for the Study of Liver Diseases recommendations limit albumin use to the specific indications above (strong recommendation)【7】.
• High‑quality (strong) evidence supports albumin for large‑volume paracentesis, while moderate‑quality evidence supports its use in spontaneous bacterial peritonitis【7】.

Albumin Use in Cirrhotic Patients with Ascites

Large‑Volume Paracentesis (≥ 5 L)

• Albumin replacement is mandatory when more than 5 L of ascitic fluid is removed. The recommendation is based on clinical trial data demonstrating renal protection. 8
• Dose: 8 g of albumin per litre of fluid removed (approximately 100 mL of 20 % albumin for every 3 L drained). This dosing scheme originates from the original Gut 2006 study. 8
• Evidence of renal benefit: In patients who did not receive albumin, 21 % developed renal impairment, whereas none did when albumin was given. (Randomized trial) 8
• Circulatory dysfunction: Albumin lowers the risk of post‑paracentesis circulatory dysfunction by 60 % (OR 0.40, 95 % CI 0.27–0.58). (Randomized trial) 8
• Hyponatremia and mortality: Compared with synthetic volume expanders, albumin reduces hyponatremia incidence by 42 % and mortality by 36 %. (Randomized trial) 8

Paracentesis < 5 L

• Albumin is not routinely required; synthetic plasma expanders (e.g., 150–200 mL gelofusine or Haemaccel) are acceptable alternatives. (Gut 2006) 8
• High‑risk patients (acute‑on‑chronic liver failure or elevated risk of post‑paracentesis AKI) may still receive albumin at 8 g/L despite the smaller volume. (Gut 2006) 8

Spontaneous Bacterial Peritonitis (SBP)

• Weight‑based dosing: 1.5 g/kg albumin administered within 6 h of SBP diagnosis, followed by 1.0 g/kg on day 3. (Gut 2006) 8

Clinical impact (meta‑analysis)

• Renal protection: Albumin reduces the risk of renal impairment by 72 % (pooled RR 0.28, 95 % CI 0.16–0.50). (Meta‑analysis) 8
• Mortality reduction: Adjunctive albumin lowers mortality by 47 % (pooled RR 0.53, 95 % CI 0.36–0.79). (Meta‑analysis) 8
• Baseline risk: Without albumin, 30 % of SBP patients develop renal dysfunction, the strongest predictor of death. (Observational data) 8
• Subgroup benefit: Patients with bilirubin > 4 mg/dL or creatinine > 1.0 mg/dL derive the greatest survival advantage from the albumin regimen. (Subgroup analysis) 8

Liver Transplant Referral

• All patients diagnosed with SBP should be evaluated for liver transplantation. This recommendation stems from the same Gut 2006 guideline source. 8